Patients were randomly assigned to receive either the low-dose pilocarpine treatment (CSF-1; Orasis Pharmaceuticals [0.4% pilocarpine hydrochloride ophthalmic solution]) or a vehicle administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback